These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30519478)

  • 1. Investigation of tolerability and quality of life for carboplatin-based chemotherapy in an elderly urothelial carcinoma patient undergoing hemodialysis: a case report.
    Kondo M; Naiki T; Hotta Y; Yamamoto Y; Sugiyama Y; Yasui T; Kimura K
    J Pharm Health Care Sci; 2018; 4():29. PubMed ID: 30519478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safe and effective administration of carboplatin-based chemotherapy in a patient undergoing hemodialysis with cancer of unknown primary by monitoring observed AUC of carboplatin-a case report].
    Kondo M; Kuroda J; Ikai Y; Hayashi R; Uegaki S; Yoshida T; Yoshida A; Komatsu H; Kimura K
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1749-52. PubMed ID: 23152033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of expected AUC of carboplatin (CBDCA) predicted by Chatelut's formula in comparison with Calvert's].
    Nakamura T; Onishi Y; Kono T; Maeda T; Wada T; Hatae M
    Gan To Kagaku Ryoho; 1997 Mar; 24(5):579-83. PubMed ID: 9087291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin-based combination chemotherapy for testicular cancer: relationship among administration dose of carboplatin, renal function and myelosuppression.
    Suzuki K; Matsumoto K; Hashimoto K; Kurokawa K; Jinbo S; Suzuki T; Imai K; Yamanaka H; Kawashima K; Takahashi H
    Hinyokika Kiyo; 1995 Oct; 41(10):775-80. PubMed ID: 8533673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Importance of AUC of carboplatin in head and neck cancer].
    Shimizu T; Yoshida M; Makishima K
    Nihon Jibiinkoka Gakkai Kaiho; 1998 Mar; 101(3):259-65. PubMed ID: 9584464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Appropriate hemodialysis scheduling based on therapeutic drug monitoring of carboplatin in a patient with lung cancer and chronic renal failure].
    Kamata H; Asano K; Soejima K; Shirahata T; Nakatani M; Inamoto H; Iketani O; Yamayoshi Y; Tanigawara Y; Ishizaka A
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1529-32. PubMed ID: 19755826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic analyses of carboplatin in a patient with cancer of the fallopian tubes undergoing hemodialysis: A case report.
    Wada T; Fukuda T; Kawanishi M; Tasaka R; Imai K; Yamauchi M; Kasai M; Hashiguchi Y; Ichimura T; Yasui T; Sumi T
    Biomed Rep; 2016 Aug; 5(2):199-202. PubMed ID: 27446541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report].
    Furuya Y; Takihana Y; Araki I; Tanabe N; Takeda M
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):1017-20. PubMed ID: 12894722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
    Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
    Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer.
    Sato E; Yano I; Jiko M; Takahashi K; Motohashi H; Masuda S; Katsura T; Nishiyama H; Segawa T; Ito N; Kamoto T; Ogawa O; Inui K
    Biol Pharm Bull; 2006 Jul; 29(7):1441-4. PubMed ID: 16819185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer (NSCLC).
    Kaplan B; Altýnbas M; Eroglu C; Karahacioglu E; Er O; Ozkan M; Bilgin M; Canoz O; Gulmez I; Gulec M
    Am J Clin Oncol; 2004 Dec; 27(6):603-10. PubMed ID: 15577439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer.
    Frasci G; Perillo G; Comella G; Comella P; Polverino M; Menzella G; Persico G
    Cancer; 1995 Apr; 75(7):1578-85. PubMed ID: 8826913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis.
    Oguri T; Shimokata T; Inada M; Ito I; Ando Y; Sasaki Y; Hasegawa Y
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):813-7. PubMed ID: 20563583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin pharmacokinetics in a patient receiving hemodialysis.
    Fong MK; Fetterly GJ; McDougald LJ; Iyer RV
    Pharmacotherapy; 2014 Feb; 34(2):e9-13. PubMed ID: 24037992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer.
    Watanabe M; Aoki Y; Tomita M; Sato T; Takaki Y; Kato N; Kikuchi M; Kase H; Tanaka K
    Gynecol Oncol; 2002 Feb; 84(2):335-8. PubMed ID: 11812097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with advanced ovarian cancer.
    Yoshida H; Sumi T; Abe K; Ishiko O
    Eur J Gynaecol Oncol; 2009; 30(5):583-5. PubMed ID: 19899423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
    Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of hematologic toxicity of carboplatin by creatinine clearance rate.
    Taguchi J; Saijo N; Miura K; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sakurai M; Minato K; Fujiwara Y
    Jpn J Cancer Res; 1987 Sep; 78(9):977-82. PubMed ID: 3117753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of whole body hyperthermia on carboplatin disposition and toxicity in dogs.
    Page RL; McEntee MC; Williams PL; George SL; Price GS; Novotney CA; Hauck ML; Riviere JE; Dewhirst MW; Thrall DE
    Int J Hyperthermia; 1994; 10(6):807-16. PubMed ID: 7884240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Carboplatin in a One-Year-Old Anuric Boy Undergoing Hemodialysis and a Review of the Literature.
    Kamei K; Sako M; Ishikawa T; Sato M; Ogura M; Uno T; Kiyotani C; Mori T; Tanaka H; Ito S; Nakamura H
    Ther Apher Dial; 2015 Oct; 19(5):491-6. PubMed ID: 25916242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.